- Home
- STRO vs IAE Comparison
STRO vs IAE Comparison
Compare STRO & IAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- IAE
- Stock Information
- Founded
- STRO 2003
- IAE 2007
- Country
- STRO United States
- IAE United States
- Employees
- STRO N/A
- IAE N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- IAE Trusts Except Educational Religious and Charitable
- Sector
- STRO Health Care
- IAE Finance
- Exchange
- STRO Nasdaq
- IAE Nasdaq
- Market Cap
- STRO 94.9M
- IAE 78.6M
- IPO Year
- STRO 2018
- IAE N/A
- Fundamental
- Price
- STRO $0.89
- IAE $7.42
- Analyst Decision
- STRO Hold
- IAE
- Analyst Count
- STRO 7
- IAE 0
- Target Price
- STRO $1.97
- IAE N/A
- AVG Volume (30 Days)
- STRO 782.2K
- IAE 46.3K
- Earning Date
- STRO 11-06-2025
- IAE 01-01-0001
- Dividend Yield
- STRO N/A
- IAE 10.21%
- EPS Growth
- STRO N/A
- IAE N/A
- EPS
- STRO N/A
- IAE N/A
- Revenue
- STRO $105,646,000.00
- IAE N/A
- Revenue This Year
- STRO $65.48
- IAE N/A
- Revenue Next Year
- STRO N/A
- IAE N/A
- P/E Ratio
- STRO N/A
- IAE N/A
- Revenue Growth
- STRO N/A
- IAE N/A
- 52 Week Low
- STRO $0.52
- IAE $5.31
- 52 Week High
- STRO $3.01
- IAE $6.45
- Technical
- Relative Strength Index (RSI)
- STRO 48.24
- IAE 51.56
- Support Level
- STRO $0.81
- IAE $7.04
- Resistance Level
- STRO $0.95
- IAE $7.36
- Average True Range (ATR)
- STRO 0.08
- IAE 0.14
- MACD
- STRO -0.00
- IAE -0.01
- Stochastic Oscillator
- STRO 53.02
- IAE 66.55
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.